- Life science stocks are under pressure due to possible NIH funding cuts. What lies ahead for the sectoron April 3, 2025 at 6:25 pm
A recent move by the Trump administration has investors fearing meaningful losses to life science tools companies.
- Supreme Court rules for the FDA in flavored vapes disputeon April 2, 2025 at 4:14 pm
The Food and Drug Administration has been reluctant to approve flavored e-cigarettes over public health concerns.
- Europe's pharma industry braces for tariffs as carve-out hopes fadeon April 2, 2025 at 4:04 pm
Europe's pharmaceutical sector is bracing for the potential impact of U.S. tariffs as hopes of an industry-wide exemption by President Donald Trump fade.
- Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaroon April 2, 2025 at 12:50 am
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.
- Hims & Hers shares rise as company adds new weight-loss medications to platformon April 1, 2025 at 11:32 pm
Hims & Hers is adding Zepbound, Mounjaro, and the generic injection liraglutide to its platform.
- Trump's tariffs are a new challenge for Big Pharma. Here are the best-positioned stockson April 1, 2025 at 7:04 pm
Leerink Partners analyst David Risinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
- Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats upon April 1, 2025 at 5:47 pm
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.